Lilly, Lupin enter diabetes partnership
NEW DELHI — Eli Lilly’s India division and Indian generic drug maker Lupin will distribute Lilly’s insulin products in India and Nepal under an agreement between the two companies announced Friday.
Under the collaboration, Lilly and Lupin will promote and distribute Huminsulin R, Huminsulin NPH, Huminsulin 50/50, Huminsulin 30/70 and Humapen Ergo II. The companies said the deal would double the current customer base.
India currently has about 51 million people living with diabetes and is expected to have 85 million by 2030, accounting for nearly one-fifth of all patients with the disease.
FDA approves subcutaneous formulation of Orencia
PRINCETON, N.J. — The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for injection under the skin to treat rheumatoid arthritis, Bristol said Friday.
The New York-based drug maker said the approval of Orencia (abatacept) for subcutaneous injection in patients with moderate to severe RA made it the first biotech drug for RA available in self-injectable and intravenous infusion formulations.
“Physicians now have a new option of a non anti-TNF, with a different mechanism of action, when administering a biologic in a subcutaneous formulation,” Stanford University Medical Center professor Mark Genovese said, referring to anti-tumor necrosis factor medications, biotech drugs that combat RA and other autoimmune disorders, by counteracting a protein that the body uses to combat tumors but also is involved in autoimmune diseases.
Lannett receives FDA approval for generic Ionamin
PHILADELPHIA — The Food and Drug Administration has approved a generic version of a short-term adjunct treatment for obesity.
Lannett said that the FDA approved its abbreviated new drug application for phentermine resin extended-release capsules in the 15-mg and 30-mg strengths. The drug, which is equivalent to UCB’s Ionamin, will be sold in bariatric clinics.
Lannett’s wholly owned pain management subsidiary, Cody Labs, will produce the active pharmaceutical ingredient for this product. The drug is indicated in the management of exogenous obesity, a form of obesity caused by excessive food intake.